Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update / image credit Timothy Garvey, MD courtesy of University of Alabama at Birmingham
Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update

September 16th 2025

EASD 2025: Findings from a subanalysis of the REDEFINE 1 phase 3 trial support Novo Nordisk's plan to advance cagrilintide into a dedicated clinical program this year.

Real-Time Continuous Glucose Monitoring Lowers Risk of Large for Gestational Age Infants in Gestational Diabetes / Image credit: ©arturfoto/AdobeStock
Real-Time Continuous Glucose Monitoring Lowers Risk of Large for Gestational Age Infants in Gestational Diabetes

September 16th 2025

Smoking Linked to Increased Risk of All Subtypes of Type 2 Diabetes / image credit Karolinska Institutet
Smoking Linked to Increased Risk of All Subtypes of Type 2 Diabetes

September 16th 2025

FDA Approves Automated Insulin Delivery System for Adults With T2D: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Automated Insulin Delivery System for Adults With T2D: Daily Dose

September 16th 2025

Approximately Half of People with Diabetes Worldwide Do Not Know They Have the Disease
Approximately Half of People with Diabetes Worldwide Do Not Know They Have the Disease: GBD Analysis

September 10th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.